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a b s t r a c t
In HIV-1 infection, plasma viral load (VL) has dual implications for pathogenesis and public health. Based
on well-known patterns of HIV-1 evolution and immune escape, we hypothesized that VL is an evolving
quantitative trait that depends heavily on duration of infection (DOI), demographic features, human
leukocyte antigen (HLA) genotypes and viral characteristics. Prospective data from 421 African
seroconverters with at least four eligible visits did show relatively steady VL beyond 3 months of
untreated infection, but host and viral factors independently associated with cross-sectional and
longitudinal VL often varied by analytical approaches and sliding time windows. Speciﬁcally, the effects
of age, HLA-Bn53 and infecting HIV-1 subtypes (A1, C and others) on VL were either sporadic or highly
sensitive to time windows. These observations were strengthened by the addition of 111 seroconverters
with 2–3 eligible VL results, suggesting that DOI should be a critical parameter in epidemiological and
clinical studies.
& 2013 Elsevier Inc. All rights reserved.
Introduction
As an informative trait speciﬁc for HIV-1 infection, plasma viral
load (VL) is well known for its strong correlation with the
probability of sexual transmission (Fideli et al., 2001; Quinn
et al., 2000) and rate of disease progression (Mellors et al., 1995,
2007). Even in individuals with uncertain duration of infection, a
relatively steady set-point VL can last for years to serve as a proxy
of host–virus equilibrium (Arnaout et al., 1999; Fiebig et al., 2003).
Factors independently associated with set-point VL range from
viral characteristics to multiple quantitative trait loci (QTLs) in the
human genome (Prentice and Tang, 2012; Yue et al., 2013),
especially genes in the human major histocompatibility complex
(MHC) that encode human leukocyte antigens (HLA) (Apps et al.,
2013; Fellay et al., 2009; Leslie et al., 2010).
The widely accepted assumption and interpretation of set-
point VL can have various problems. For example, HIV-1
immune escape can frequently tip the initial equilibrium in
favor of the virus (Crawford et al., 2009; Kawashima et al., 2009;
Mellors et al., 1995), which may obscure the relationship
between set-point VL and HIV-1 disease progression (Mellors
et al., 2007; Rodriguez et al., 2006). A second issue relates to
various statistical methods that either fully embrace the concept
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of set-point VL (Prentice and Tang, 2012) or provide two
alternative strategies, i.e., mixed model for repeated measures
(Prentice et al., 2013; Shrestha et al., 2009; Tang et al., 2011) and
assessment of cumulative viral load burden (Arnaout et al.,
1999; Cole et al., 2010; Mugavero et al., 2011). To establish the
advantages and disadvantages of these analytical approaches,
we have tested a central hypothesis that cross-sectional and
longitudinal VL data are evolving outcomes that depend heavily
on duration of infection DOI), demographic features, HLA geno-
types and viral characteristics.
Results
Characteristics of 421 HIV-1 seroconverters (SCs) in the study
population
For this study, sufﬁcient prospective data were available for 421
SCs from Zambia (Lusaka and Copper Belt, n¼164), Uganda
(Entebbe and Masaka, n¼110), Kenya (Kiliﬁ and Nairobi, n¼83)
and Rwanda (Kigali, n¼64) (Table 1). In each subgroup, males
outnumbered females, especially in Kenya. All volunteers were
relatively young at enrollment (mean age between 25.1 and 33.6
years by site). The estimated dates of infection (EDI) ranged from
May 2005 to March 2011, being highly comparable across study
sites. Based on a 1.3-kb fragment of the HIV-1 pol gene sequences
(successful in 93.4% of SCs), subtypes A1 and C accounted for 74.2%
of the total, while other subtypes (B or D) and recombinant forms
were infrequent, precluding further stratiﬁcation (Table 1).
As reported earlier (Prentice et al., 2013; Tang et al., 2011), HIV-
1 subtypes A1 and C were predominant in Rwandan and Zambian
SCs, respectively. Kenyan SCs differed from others in their lower
age (25.174.4 years), high male-to-female ratio (5.9), and pre-
valence of multiple infecting HIV-1 subtypes (A1, C, D and others)
(6.0–69.9% per subtype). Ugandan SCs had the greatest frequency
(52.8%) of non-A1 and non-C subtypes (mostly subtype D) (Table 1).
The spectrum of VLs and cumulative viremia (VCY) in 421 SCs during
early HIV-1 infection
In the 3–24 months interval after EDI, VL was measured at a
total of 3154 person-visits. Cross-sectional VLs beyond 3 months of
infection ranged from below detection (o2.60 log10 copies/mL) to
6.6 log10. The mean log10 VL in SCs from each country was stable,
with little (r0.40 log10) ﬂuctuation between visit intervals, espe-
cially adjacent intervals (r0.30 log10) (Table 1). Geometric mean
VLs were also quite similar between year 1 and year 2 (r0.30 log10).
On the other hand, country-speciﬁc variations in VLs began to
emerge during later visits (Po0.001 by ANOVA) (Table 1). Reﬂecting
a strong collinearity between region (geography) and HIV-1 sub-
types, Zambian SCs consistently had higher VLs than Kenyan and
Rwandan SCs for the 18–24 months VL, year 2 geometric mean VL
and cumulative viremia (Po0.05 in all six comparisons).
Evaluation of linear correlation between longitudinal
and cross-sectional VL data
In 56 (87) pairwise comparisons of eight distinct outcomes of
VL, the Pearson r values ranged from 0.51 to 0.92 before and after
statistical adjustments for age, sex, country of origin, and duration
Table 1
Characteristics of 421 HIV-1 seroconverters enrolled from four African countries.
Characteristicsa and HLA variants of major interest Kenya Rwanda Uganda Zambia
Number of seroconverters with sufﬁcient data 83 64 110 164
Sex ratio (M/F) 5.9 (71/12) 1.4 (37/27) 1.4 (65/45) 1.3 (92/72)
Age: mean7SD (year) 25.174.4 31.878.9 31.978.3 33.678.0
AgeZ40 year: no. (%) 0 (0.0) 11 (16.9) 22 (20.0) 34 (20.7)
Estimated dates of infection
Earliest November 2005 May 2005 September 2005 June 2005
Latest February 2011 January 2011 September 2010 March 2011
Person-visits with eligible viral load (VL) data (3–24 months) 617 486 862 1189
HIV-1 subtypeb: no. (%)
A1 58 (69.9) 50 (78.1) 41 (37.3) 0 (0.0)
C 8 (9.6) 7 (10.9) 5 (4.6) 144 (87.8)
D 8 (9.6) 1 (1.5) 52 (47.3) 0 (0.0)
Others (B and recombinants) 5 (6.0) 3 (4.7) 6 (5.5) 2 (1.2)
Unknown (no viral sequencing) 4 (4.8) 3 (4.7) 6 (5.5) 18 (11.0)
Cross-sectional viral load (VL): mean7SD (in log10)
3–6 Months 4.271.0 4.171.1 4.471.0 4.571.0
6–9 Months 4.470.9 4.171.0 4.371.1 4.470.9
9–12 Months 4.171.0c 4.171.0c 4.371.0 4.570.9
12–18 Months 4.270.8 4.171.0c 4.271.2 4.570.8
18–24 Months 4.071.1c 4.071.1c 4.171.2c 4.670.8
Repeated VL measurements (in log10)
Year 1 geometric mean (3–12 months): mean7SD 4.370.9 4.171.0 4.371.0 4.470.9
Number of VLs taken within year 1: median (IQR) 3 (3–4) 3 (3–5) 3 (3–4) 3 (3–4)
Year 2 geometric mean (13–24 months): mean7SD 4.170.9c 3.971.1c 4.271.0 4.570.7
Number of VLs taken within year 2: median (IQR) 4 (4–4) 4 (4–4) 4 (4–4) 4 (3–4)
Viremia copy years (VCY) (3–24 months): mean7SD 4.770.7c 4.670.8c 4.770.9 5.070.6
Number of VLs used for calculating VCY: median (IQR) 7 (7–8) 7 (7–8) 7 (7–9) 7 (6–8)
HLA-Bn18 (Bn18:01) 5 (6.0) 5 (7.8) 10 (9.1) 11 (6.7)
HLA-Bn45 (Bn45:01) 18 (21.7) 4 (6.3) 15 (13.6) 26 (15.9)
HLA-Bn53 (Bn53:01) 14 (16.9) 10 (15.6) 22 (20.0) 29 (17.7)
HLA-Bn57 (mostly Bn57:03) 8 (9.6) 6 (9.4) 10 (9.1) 17 (10.4)
a Non-standard abbreviations: IQR, interquartile range (25th to 75% percentile); SD, standard deviation of the mean; AUC, area under the VL curve.
b The minor HIV-1 subtypes (B, D, and others) are combined for analysis. Unknown subtypes were assigned based on probabilities (see text).
c Statistically signiﬁcance differences when compared with data from Zambians.
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of infection (Po0.0001 for all tests) (Table 2). For the seven cross-
sectional VL measurements with slight variation in effective
sample sizes (n¼381–419), the overall pattern persistently
revealed that correlation was weak unless the tests involved
cross-sectional results from two adjacent visits (e.g., 3–6 months
versus 6–9 months and 9–12 months versus 12–18 months). Even
so, correlation that was strong enough to imply two mutually
interchangeable outcomes (i.e., r240.80) was rare, being detected
on a single occasions. In this case, the 6–9 months set-point VL
showed a strong collinearity with the geometric mean VL during
the 3–12 months interval regardless of statistical adjustments
(r¼0.92, r2¼0.85, and Po0.0001). In addition, as far as the
adjusted r values were concerned, country of origin as a covariate
was interchangeable with HIV-1 subtype as a covariate.
Identiﬁcation of independent correlates of longitudinal viremia
in 421 SCs
On the basis of adjusted statistical signiﬁcance (Po0.05),
multivariable models identiﬁed sex, duration of infection, infecting
HIV-1 subtypes, and HLA-B genotypes as independent predictors
of longitudinal VL outcomes (Table 3). These factors, along with
age, accounted for about 5% of the overall variability in the VL
dataset (Po0.0001). Ranking by univariable r2 values placed viral
subtype C, HLA-Bn57, and sex as the top three predictors. Alter-
natively, the top three predictors ranked by unadjusted VL differ-
ences (mean beta estimates) were HLA-Bn57 (Po0.0001), HLA-
Bn18 (P¼0.018), and sex (Po0.0001) (Table 3).
However, heterogeneity in HIV-1 viremia ﬂuctuated over time
when SCs deﬁned by host and viral factors were compared. For
example, clear separation in VL was seen between HLA-Bn18
positive and HLA-Bn18 negative SCs throughout the 3–24 months
interval, but differences between HIV-1 subtypes A1 and C were
not apparent in the 3–9 months period (Fig. 1). Like HLA-Bn18,
Bn45, Bn57 and female sex also had highly persistent effects on VLs
during the study intervals; these relationships were readily con-
ﬁrmed by analyses of cumulative viremia (data not shown).
Viral and host factors associated with cross-sectional viremia:
sensitivity analyses based on generalized linear regression models
(GLMs)
Analyses of seven cross-sectional VL outcomes led to highly
variable ﬁndings (Table 4). The number of independent predictors
ranged from two (sex and HLA-Bn45) for the 3–6 months VL to six
(all but HIV subtype) for the 6–9 months VL. HLA-Bn18 and Bn45 as
unfavorable factors were each detected in 4 out of 6 models,
without a clear preference for early or later intervals (Table 4).
HLA-Bn57 was a favorable factor in 5 out of 6 models, with an
effect size exceeding 0.30 log10 after the ﬁrst 6 months of infection.
Overall, host and viral factors explained 7.2–14.8% of variability in the
six VL cross-sectional phenotypes (Po0.0001 in each test). Of note,
analyses of GM VLs had little advantage over individual VLs.
Findings based on alternative approaches
In alternative analyses, HIV-1 VL dynamics differed between
eastern and southern Africa (Po0.0001) (Fig. 2), which was
consistent with differences seen with HIV-1 subtypes. In addition,
analyses guided by LOESS curves revealed that HLA-Bn53 had
Table 2
Relationships of cross-sectional viral load (VL) and cumulative viremia (VCY) in early HIV-1 infection, as deﬁned by Pearson correlation coefﬁcients (r).a
VL measurements (no. of subjects) Cross-sectional (set-point) VL at ﬁve intervals Repeated measures VCY
3–6 Months 6–9 Months 9–12 Months 12–18 Months 18–24 Months 3–12 Months 13–24 Months 3–24 Months
3–6 Months (381) 1.00 0.76 0.69 0.65 0.52 0.88 0.62 0.72
6–9 Months (394) 0.74 1.00 0.77 0.73 0.58 0.92b 0.70 0.80
9–12 Months (404) 0.68 0.76 1.00 0.75 0.61 0.88 0.75 0.82
12–18 Months (416) 0.63 0.71 0.74 1.00 0.69 0.79 0.86 0.86
18–24 Months (408) 0.51 0.57 0.61 0.68 1.00 0.64 0.90 0.78
3–12 Months, geometric mean (419) 0.88 0.92b 0.88 0.77 0.63 1.00 0.77 0.87
13–24 Months, geometric mean (418) 0.61 0.70 0.74 0.85 0.89 0.76 1.00 0.90
3–24 Months, VCY (421)b 0.71 0.79 0.82 0.85 0.77 0.87 0.89 1.00
a With log10-transformation before analysis, the r values below the diagonal are for the raw data, while r values above the diagonal (shaded gray) are adjusted for age,
sex, country of origin, and duration of infection (wherever applicable) (Po0.001 for all pairwise tests).
b The R2 values exceed 0.80 in four tests only (shown in bold).
Table 3
Analyses of longitudinal viral load (VL) data (repeated measurements) in early HIV-1 infection (the 3–24 months interval after infection).
Predictors (independent variables) Effects by univariable modelsb Multivariable modelc
Δ7SE P R2 Δ7SE P
Age 440 years 0.0870.11 0.494 0.000 0.1470.11 0.191
Female sex 0.3670.08 o0.0001 0.038 0.3770.08 o0.0001
HIV-1 subtype Ca 0.2470.08 0.004 0.028 0.3870.09 o0.0001
Other HIV-1 subtypesa 0.1370.10 0.227 0.002 0.3470.11 0.002
Duration of infection (quarterly) 0.0270.00 0.009 0.007 0.0270.00 0.008
HLA-Bn18 0.3770.16 0.018 0.012 0.3770.15 0.013
HLA-Bn45 0.2570.12 0.028 0.008 0.2570.11 0.021
HLA-Bn57 0.5370.14 0.0001 0.016 0.4770.13 0.0003
Overall summary statistics NA
r2¼0.049, Po0.0001
a HIV-1 subtype A is the reference group.
b Top three predictors ranked by the effect size are underlined.
c Based on simultaneous evaluation of all factors as shown. For consistency with reported approach (Tang et al., 2002b), age is kept as a covariate in all multivariable
models (here and Table 3) regardless of statistical signiﬁcance.
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modest association with VL in the 3–18 months intervals (2361
person-visit, P¼0.043) (Fig. 2). VLs in the 75 subjects with HLA-Bn53
had a unique pattern: a modest separation between Bn53-positive
and Bn53-negative subjects (average Δ¼0.2170.1 log10) faded
shortly after the 18 months mark (Fig. 2). In the ﬁnal round of data
analyses for all 532 eligible SCs (Table 5), HLA-Bn53 explained 1.1% of
the overall variance in longitudinal VLs (P¼0.055 by univariable
analysis), while the multivariable model conﬁrmed its independent
association with longitudinal VLs (adjusted P¼0.025).
Additional observations on HLA variants
Among the four HLA variants independently associated with
longitudinal VLs (Table 5), HLA-Bn18, Bn53 and Bn57 had similar
distribution in the four African countries (Table 1). Two-thirds of
subjects with Bn57 had HLA-Bn57:03, which had its own associa-
tion with reduced viremia (data not shown). On the other hand,
HLA-Bn18, Bn53 and Bn45 were each represented by a single allele
(Bn18:01, Bn53:01 and Bn45:01, respectively) regardless of study
Fig. 1. Contrasting dynamics of HIV-1 viremia in African seroconverters deﬁned by host and viral genotypes. Prospective viral load measurements are compared between
HLA-Bn18-positive and HLA-Bn18-negative subjects (top panel, 3154 person-visits) and between two major HIV-1 subtypes, HIV-1C and HIV-1A (bottom panel, 2306 person-
visits). Thick and thin lines correspond to the expected mean (average) value and 95% conﬁdence intervals for each stratum (see Table 3 for summary statistics based on
mixed models). Arrows point to plasma viral load measurements that are o400 RNA copies/mL (transformed to 1.30 log10).
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sites. Other HLA alleles relevant to Africans, including An29, An36,
An74, Bn13, Bn14, Bn35, Bn39, Bn42, Bn51, Bn58:01, Bn58:02, Bn81,
Cn04, Cn18, and the An30þCn03 combination (Apps et al., 2013;
Leslie et al., 2010; McLaren et al., 2012; Tang et al., 2010), had
minimal impact on VL outcomes (data not shown). Alternative
analyses of structurally deﬁned HLA-A and HLA-B supertypes were
inconclusive (data not shown).
Discussion
Through systematic analyses of prospective data from African
seroconverters with early HIV-1 infection, our work demonstrated
that cross-sectional VL outcomes change rapidly as the infection
progresses. In other words, VLs separated by as little as 3 months
can be considered as different outcomes (Table 2) with varying
correlates (Table 4). For subgroups of SCs deﬁned by host and viral
factors (Table 4), three patterns of local regression curves (Figs. 1 and
2) represent (i) steady and robust differences across visits, (ii)
convergence followed by gradual divergence, and (iii) divergence
followed by gradual convergence. Other patterns (e.g., wave-like and
U-shaped) were less obvious, probably because the overall study
interval (from 3 to 24 months after EDI) was relatively short.
In previous work based on 269 SCs (homosexual men in the US)
with semi-annual follow-up visits, VL trajectories (slopes) during
the ﬁrst 3 years after seroconversion correlated with AIDS-free
time, while VLs in the 3 years immediately before AIDS diagnosis
had no predictive values (Lyles et al., 1999). When stratiﬁed by
host genotypes, SCs from the same study showed different
patterns of VL dynamics in early infection as well (Tang et al.,
2002a). While our new ﬁndings here are largely consistent with
the reports from the Multicenter AIDS Cohort Study, three major
advantages in study design and analytical approaches here can
help strengthen the search for underlying mechanisms. First,
frequent testing before and during seroconversion (at monthly to
quarterly visits) has improved the precision in assigning EDI and
DOI. Second, follow-up visits after seroconversion are frequent
enough to facilitate the comparison of early virologic outcomes in
sliding time windows (Table 4). Third, host and viral genotypes can
be analyzed jointly in multivariable models. The two major HIV-1
subtypes, A1 and C, are widespread in sub-Saharan Africa
(Osmanov et al., 2002; Tebit and Arts, 2011), with some evidence
for disparity in evolutionary and pathophysiologic attributes when
compared with other subtypes (Baeten et al., 2007; Kaleebu et al.,
2001; Kiwanuka et al., 2008; Vasan et al., 2006). VL differences
between HIV-1 subtypes A1 and C infection (Table 3 and Fig. 1) are
generally consistent with the contrasting rates of heterosexual
HIV-1 transmission in Rwanda and Zambia where the respective
subtypes predominate (Dunkle et al., 2008; Fideli et al., 2001).
Recent assessment of disease progression (time to severe
immunodeﬁciency) has revealed the role of African HIV-1 sub-
types in pathogenesis (Amornkul et al., in press). However, given
the strong collinearity between geography and HIV-1 subtypes
(Table 1), a more deﬁnitive elucidation of host and viral factors in
HIV-1 pathogenesis in Africa may require the assembly of a
genetically homogeneous cohort with diverse HIV-1 subtypes
and adequate follow-up. Such study is no longer feasible as new
treatment guidelines recommended by the World Health Organi-
zation are expected to transform the test-and-treat concept into a
global practice (Cohen et al., 2011; Montaner et al., 2010;
Mugavero et al., 2012).
Among the three HLA-B variants independently and persis-
tently associated with VL heterogeneity, HLA-Bn57 is a well-known
favorable factor, while HLA-Bn18 and HLA-Bn45 are consistently
unfavorable in multiple studies (Apps et al., 2013; Lazaryan et al.,
2011; Leslie et al., 2010; McLaren et al., 2012; Tang et al., 2010).
Generalizable ﬁndings about these HLA-B variants, now in the
context of sub-Saharan African populations, should beneﬁt future
epidemiologic and experimental studies, especially in the context
of HIV-1 adaptation at the population level (Kawashima et al.,
2009). HLA-Bn18 has also been reported as partially protective
against mother-to-child HIV-1 transmission in Kenyan infants
(Farquhar et al., 2004), suggesting again that mechanisms for
immune control of established HIV-1 infection can be quite
distinct from those mediating acquisition of infection (Gao et al.,
2010; Song et al., 2011; Tang et al., 2008).
HLA allelic products contribute to immune control of viral
infection through both innate and adaptive immune pathways
(Carrington et al., 2008; Merino et al., 2012, 2013; Stewart et al.,
2005). Alleles with early inﬂuences on HIV-1 infection tend to
impose a strong selection pressure for viral immune escape
mutations—a phenomenon that has been repeatedly examined in
individuals with HLA-Bn57 and related alleles (Bansal et al., 2007;
Crawford et al., 2009; Leslie et al., 2004; Novitsky et al., 2010;
Wang et al., 2009). The unfavorable effect of HLA-Bn18 on VL
started early and remained stable (Fig. 1), which may translate to a
durable impact on HIV-1 pathogenesis. In settings where treat-
ment priority is necessary, timely interventions directed to sub-
jects carrying unfavorable HLA proﬁle may maximize the beneﬁts
by preventing pathogenesis as well as transmission.
Table 4
Sensitivity analyses using cross-sectional viral load (VL) results in early HIV-1 infection (multivariable models)a.
Predictors (independent variables) Individual and joint effects on cross-sectional VLsd Geometric Meand
3–6 Months 6–9 Months 9–12 Monthse 12–18 Months 18–24 Months 13–24 Months
Age 440 years 0.1270.1 0.2970.1n 0.2170.1 0.1870.1 0.1270.1 0.1370.1
Female gender 0.3870.1nnn 0.5070.1nnn 0.3270.1nn 0.5070.1nnn 0.3270.1nn 0.3670.1nnn
HIV-1 subtype Cb 0.2270.1 0.2070.1 0.2770.1n 0.3870.1nnn 0.6670.1nnn 0.5170.1nnn
Other HIV-1 subtypesb 0.2670.1 0.2270.1 0.3170.1n 0.3370.1nn 0.3970.1nn 0.4070.1nnn
Duration of infection (monthly) 0.1070.1 -0.1170.1n 0.0670.1 0.0470.1 0.0570.0 NA
HLA-Bn18 0.2770.2 0.5470.2nn 0.4870.2nn 0.4870.2nn 0.2570.2 0.4070.2n
HLA-Bn45 0.3070.1n 0.3270.1n 0.2170.1 0.1170.1 0.3870.1nn 0.2270.1
HLA-Bn57 0.2070.2 0.4170.2n 0.5870.2nnn 0.5770.1nnn 0.4670.2nn 0.5170.1nnn
Overall R2 for each modelc 0.072 0.129 0.104 0.152 0.137 0.151
a Individual predictors are deﬁned in Table 3.
b HIV-1 subtype A serves as the reference group.
c Overall Po0.0001 for all tests.
d The cross-sectional outcomes are deﬁned in Table 1. Summary statistics correspond to mean difference (beta estimate)7standard error of the mean. Statistical
signiﬁcance is shown at three levels (n for Po0.05; nn for o0.01, and nnn for o0.001).
e Estimates here are virtually identical to those based on the analysis of 3–12 months geometric mean VLs (overall r2¼0.108).
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Our work also indicates that modest and relatively transient
effects attributable to host factors like HLA-Bn53 can easily escape
detection when VLs in the ﬁrst few months of infection are missed
(Fig. 2). As a common allele in Africans and African–Americans, its
relevance to HIV-1 infection has been highlighted in at least two
recent studies (Apps et al., 2013; Lazaryan et al., 2011). Although
VLs were only slightly elevated in Africans subjects with HLA-Bn53
during the ﬁrst 18 months of infection (Fig. 2), the potential
impact on HIV-1 reservoir and transmission rate may deserve
some investigation.
Conclusions
Analyses of cross-sectional data often failed to identify host and
viral factors (e.g., HLA-Bn53 and HIV-1 subtypes) due to time-
varying associations with VLs, even in early infection when
complications by immune escape, co-infection and other forms
of comorbidities should be minimal. For correlates (e.g., HLA-Bn57)
that can be readily identiﬁed using randomly chosen phenotypes,
the magnitude of associations can vary from one interval to
another. These observations continue to support our notion that
Fig. 2. Viremia in HIV-1 seroconverters stratiﬁed by geography and HLA-Bn53. Prospective viral load measurements (3154 person-visits) are compared between Eastern
Africa (Kenya, Rwandan and Uganda) and Southern Africa (Zambia) (top panel) and between HLA-Bn53-positive and negative subgroups (bottom panel). Thick and thin lines
correspond to the expected average value and 95% conﬁdence intervals for each stratum (overall unadjusted P¼0.056). Arrow points to plasma viral load measurements that
are o400 RNA copies/mL (transformed to 1.30 log10).
H.A. Prentice et al. / Virology 449 (2014) 254–262 259
DOI is an important parameter when cross-sectional VL results are
assessed in clinical research (Prentice et al., 2013; Prentice and
Tang, 2012; Tang et al., 2010). As early diagnosis of HIV-1 infection
remains costly and difﬁcult (Kozak et al., 2013), few studies can
actually assess the timing of VL measurements in prevalent HIV-1
infection. One reasonable compromise is to down-play ﬁndings
based solely on random sampling of cross-sectional data. Alter-
natively, immunologic and virologic techniques suitable for infer-
ring DOI in seroprevalent infection (Cousins et al., in press) may
provide valuable information about DOI.
Materials and methods
Study population
Recent HIV-1 seroconverters (SCs) were enrolled from Kenya,
Rwanda, Uganda, and Zambia (Table 1) under a uniform study protocol
developed and implemented by the International AIDS Vaccine
Initiative (IAVI) (Amornkul et al., in press). The procedures for written
informed consent and research activities were approved by institu-
tional review boards at all collaborating clinical research centers, with
further compliance to human experimentation guidelines set forth by
the United States Department of Health and Human Services.
Follow-up strategies before and after HIV-1 infection
Identiﬁcation of SCs relied on frequent (monthly to quarterly)
testing of HIV-1 seronegative subjects at high risk of HIV-1
infection through heterosexual (common) and homosexual (occa-
sional) exposure, with the vast majority being partners of HIV-1
discordant couples and/or individuals diagnosed with sexually
transmitted infections. As described in detail elsewhere
(Amornkul et al., in press; Karita et al., 2007; Prentice et al.,
2013), the estimated dates of HIV-1 infection (EDI) were deﬁned as
one of the following: (i) the midpoint between the last seronega-
tive and ﬁrst positive HIV-1 antibody tests; (ii) 2 weeks before the
ﬁrst positive test for HIV-1 p24 antigen in plasma; (iii) 10 days
before the ﬁrst positive test for plasma viral load (VL) while being
negative for both p24 and rapid HIV-1 antibody tests; and (iv)
event date for the only high-risk exposure. Following conﬁrmation
of HIV-1 infection (detection of VL), clinical visits were scheduled
monthly for the ﬁrst 3 months after EDI and quarterly for the 3–24
months interval. Initiation of antiretroviral therapy (ART) followed
national guidelines (Ngongo et al., 2012), and all visits and VL
measurements after ART initiation were excluded. In all, 421 SCs
(Table 1) were selected based on (i) availability of more than 50
SCs from a single country, with biological specimens for DNA
extraction and HLA class I genotyping, (ii) at least four time points
of VL in the early chronic phase (3–24 months) of infection, with
no gap greater than 1 year between two consecutive VL measure-
ments, and (iii) no ART during the eligible study intervals. An
additional 111 SCs with only 2–3 eligible VL measurements were
available for secondary analyses. The remaining SCs excluded from
analyses here included those enrolled from South Africa (n¼26)
and a small group (n¼46) with limited follow-up (no more than a
single VL for eligible visits).
HIV-1 viral load (VL) as a quantitative trait
Plasma VL (RNA copies/mL) was measured at a central location
(Clinical Laboratory Services, Johannesburg, South Africa) using the
Amplicor Monitor v1.5 assay (Roche Applied Science, Indianapolis, IN)
and following good clinical laboratory practices (Amornkul et al., in
press). With a focus on visits beyond acute-phase (the ﬁrst 3 months
after EDI), eligible VLs in the 3–24 months intervals were ﬁrst treated
as the longitudinal outcome and then divided into cross-sectional
outcomes corresponding to ﬁve visit intervals: 3.1–6.0 months, 6.1–9.0
months, 9.1–12.0 months, 12.1–18.0 months and 18.1–24.0 months
(rounded to the nearest integer for tables and ﬁgures). Repeated
measures in the 3.1–12.0 and 12.1–24.0 months intervals also allowed
the calculation of geometric mean (GM) VLs. In addition, cumulative
viremia as a time‐varying measurement of VL in the 3.1–24.0 months
after EDI was expressed as the number of virus copies per mL of
plasma multiplied by time of follow-up (years) (Cole et al., 2010;
Mugavero et al., 2011). A trapezoidal rule was used to approximate the
integral representing the area under the curve for each participant's
longitudinal VL. Within each segment (time between two VL sampling
dates), VL burden was the mean of the two VL measurements
multiplied by the time interval between the sampling dates. Summa-
tion of the individual segments (3–24 months after EDI) gave rise to
the viremia copy-year (VCY) outcome. For log10 transformation, all VLs
below the lower limit of detection (LLD¼400 RNA copies/mL) were
assumed to be 1.30 (half of log10400). In alternative analyses, setting
VL below LLD to 2.30 log10 (200 copies/mL) did not change statistical
models (data not shown).
Viral sequencing and human leukocyte antigen (HLA) class I
genotyping
Methods for HIV-1 pol gene sequencing and HLA class I
genotyping have been described elsewhere (Price et al., 2011;
Table 5
Sensitivity analyses using longitudinal viral load (VL) data from 532 seroconverters who have at least two VL data points during the 3–24 months interval after infection.
Predictors (independent variables) Effects by univariable modelsb Multivariable modelc
Δ7SE P R2 Δ7SE P
Age 440 years 0.0570.10 0.611 0.000 0.1170.08 0.237
Female sex 0.3570.08 o0.0001 0.025 0.3870.10 o0.0001
HIV-1 subtype Ca 0.2670.08 0.001 0.020 0.3770.08 o0.0001
Other HIV-1 subtypesa 0.1070.10 0.320 0.001 0.2970.10 0.003
Duration of infection (monthly) 0.0170.00 0.001 0.007 0.0170.00 0.001
HLA-Bn18 0.3370.15 0.025 0.007 0.3670.14 0.001
HLA-Bn45 0.2870.10 0.005 0.013 0.2770.10 0.006
HLA-Bn53 0.1870.10 0.055 0.011 0.2070.09 0.025
HLA-Bn57 0.5070.13 o0.0001 0.012 0.4670.12 o0.001
Overall summary statistics NA R2¼0.041, Po0.0001
a HIV-1 subtype A is the reference group.
b Top three predictors ranked by the effect size are underlined.
c Based on simultaneous evaluation of all factors as shown. For consistency with reported approach (Tang et al., 2002b), age is kept as a covariate in all multivariable
models (here and Table 3) regardless of statistical signiﬁcance.
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Tang et al., 2011). Viruses were grouped into subtypes (mostly A1,
C and D) and recombinant forms (rare) (Table 1). Allelic variants at
three HLA class I loci (HLA-A, HLA-B and HLA-C) were fully resolved
to the 4-digit level. Data analyses focused on three prominent
variants, HLA-Bn18 (unfavorable), Bn45 (unfavorable), and -Bn57
(favorable), based on their conﬁrmed effects on VL in native
Africans and African–Americans (Apps et al., 2013; Leslie et al.,
2010; Tang et al., 2010).
Statistical analysis
Using software packages in SAS, version 9.2 (SAS Institute, Cary,
NC), SCs were stratiﬁed by country of origin and tabulated for
demographic data, laboratory ﬁndings (viral subtypes and VL)
(Table 1) and distribution of major HLA variants of interest.
Methods used for comparing baseline characteristics included
(i) analysis of variance (ANOVA), (ii) t-test for quantitative vari-
ables with a normal distribution, and (iii) χ2 and Fisher exact tests
for categorical variables. The extent of collinearity among eight VL
outcomes was determined by Pearson's correlation coefﬁcients (r),
and paired data with rZ0.90 (r2Z0.80) were considered as
mutually interchangeable (Craney and Surles, 2002). Subsequent
association analyses, including mixed models, generalized linear
models (GLMs) and local regression (LOESS) curves, aimed at
identifying independent correlates of VL and assessing their
relative effects on VL over time during the 3–24 months follow-
up period. Based on evidence from earlier studies (Prentice et al.,
2013; Tang et al., 2010), age, sex, duration of infection (DOI,
measured monthly or quarterly), infecting viral subtypes and
common HLA variants were tested as independent cofactors in
univariable and multivariable models. The performance of indivi-
dual models was gauged by their overall R2 values (corresponding
to variability explained by factors in the model), while the
performance of individual factors was ranked ﬁrst by the regres-
sion beta (mean difference) and then by the R2 values from
univariable models. Statistical signiﬁcance was accepted at the
level of Pr0.05, but age was kept in all multivariable models
regardless of statistical signiﬁcance (for consistency with earlier
work). Major ﬁndings from these models were subjected to three
sets of sensitivity analyses: (i) replacing HIV-1 subtype with
country of origin as the two covariates were highly collinear
(Tang et al., 2011); (ii) including regional groupings (eastern versus
southern Africa) as a covariate (Prentice et al., 2013); and (iii)
adding the results from 111 eligible SCs with limited (2–3) VL data
points to the overall model for repeated VL measurements.
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